While CD8+ T cells constitute the predominant subset of TILs and play a crucial role in immune responses in solid tumors, only a few subsets have strong anti‐tumor capabilities through targeting tumor antigens, regulating immune cell chemotaxis, and secreting cytotoxic factors.[32, 33] Our previous study has demonstrated that CD8+TRM cells with neoantigen‐specific TCR may be a promising immunotherapeutic target for HCC.[27] However, the key subset of MSS‐CRLM still needs to be deeply explored. This evidence concerns the gene CD8A and neoplasm.